With recent approval of gene replacement therapy Luxturna, for the treatment of RPE65-related retinal disease, the precedence for approval of future gene-based therapies has been set and results of the RPGR early phase clinical trials are awaited with great expectation. The gene discussed is RPE65; the disease is Abnormal retinal morphology.